Yongming Fu
Key Laboratory Of Clinical Precision Pharmacy Of Guangdong Higher Education Institutes
Guangzhou, China
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
A Hybrid compound H93 treats prostate cancer by directly binding UHRF1 and promoting protein dimerization.
Journal: Communications chemistry
Published: March 28, 2025
A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.
Journal: Oncogene
Published: September 22, 2024
Roles of post-translational modifications of UHRF1 in cancer.
Journal: Epigenetics & chromatin
Published: March 01, 2024
SKP2 inhibition activates tumor cell-intrinsic immunity by inducing DNA replication stress and genomic instability.
Journal: British journal of cancer
Published: January 24, 2024
ATM-Mediated translocation of RanBPM regulates DNA damage response by stabilizing p21 in non-small cell lung cancer cells.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: August 23, 2023
PLK1 maintains DNA methylation and cell viability by regulating phosphorylation-dependent UHRF1 protein stability.
Journal: Cell death discovery
Published: November 28, 2022
AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 26, 2022
UHRF1 promotes spindle assembly and chromosome congression by catalyzing EG5 polyubiquitination.
Journal: The Journal of cell biology
Published: October 24, 2022
Diosgenin inhibits prostate cancer progression by inducing UHRF1 protein degradation.
Journal: European journal of pharmacology
Published: September 20, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026